November 12, 2008
EntreMed Reports Clinical Program Progress and Company UpdateNovember 10, 2008
EntreMed’s MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical TrialNovember 07, 2008
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare ConferenceNovember 06, 2008
EntreMed Reports Third Quarter 2008 Financial ResultsNovember 03, 2008
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis ModelsOctober 23, 2008
EntreMed’s ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer ModelOctober 10, 2008
EntreMed to Present at BioPartnering Europe ConferenceOctober 02, 2008
EntreMed Announces Stock Listing Transfer to Nasdaq Capital MarketAugust 12, 2008
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase ProgramAugust 06, 2008
EntreMed Reports Second Quarter 2008 Financial ResultsJune 18, 2008
EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business DevelopmentJune 13, 2008
EntreMed to Present at the BIO 2008 Annual International ConventionJune 11, 2008
EntreMed Receives New Patent for 2-Methoxyestradiol AnalogsJune 03, 2008
EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual MeetingJune 02, 2008
EntreMed’s ENMD-2076 Demonstrates Antitumor Activity in Multiple Myeloma ModelMay 13, 2008
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare ConferenceMay 08, 2008
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed’s Selective Kinase InhibitorMay 02, 2008
EntreMed Reports First Quarter 2008 Financial ResultsApril 22, 2008
EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual MeetingApril 16, 2008
EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
